Abstract
Background Activating mutation of KIT or PDGFRA is the primary molecular mechanism for gastrointestinal stromal tumors (GISTs). Although imatinib has ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
